Gleevec (imatinib mesylate) in 16 patients with chronic myelomonocytic leukemia (CMMoL).

被引：0

作者：

Raza, A ^{[1
]}

Lisak, L ^{[1
]}

Dutt, D ^{[1
]}

Syed, E ^{[1
]}

Dean, L ^{[1
]}

Fantroy, L ^{[1
]}

Gezer, S ^{[1
]}

Reddy, P ^{[1
]}

Hsu, WT ^{[1
]}

Goldberg, C ^{[1
]}

Loew, J ^{[1
]}

Venugopal, P ^{[1
]}

机构：

[1] Rush Univ, MDS Ctr, Chicago, IL 60612 USA

来源：

BLOOD | 2001年 / 98卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4829

引用

页码：273B / 273B

页数：1

共 50 条

[1] Laboratory monitoring of chronic myelogenous leukemia patients on imatinib mesylate (Gleevec) therapy
Shaw, GR
LABORATORY MEDICINE, 2004, 35 (02) : 104 - 106
[2] CHRONIC MYELOMONOCYTIC LEUKEMIA (CMMOL) PLUS THE MYELODYSPLASTIC SYNDROME
WICKRAMANAYAKE, PD
PALLENSCHAT, J
DIEHL, V
MEDIZINISCHE KLINIK, 1991, 86 (08) : 383 - 386
[3] Imatinib mesylate (Gleevec®/Glivec®):: A new therapy for chronic myeloid leukemia and other malignancies
Hernández-Boluda, JC
Cervantes, F
DRUGS OF TODAY, 2002, 38 (09) : 601 - 613
[4] Symptomatic response to imatinib mesylate in cutaneous mastocytosis associated with chronic myelomonocytic leukemia
Vannorsdall, E. J.
Collins, J. A.
Chen, Q. C.
Sarai, G.
Baer, M. R.
CURRENT ONCOLOGY, 2013, 20 (04) : E349 - E353
[5] Imatinib Mesylate (Gleevec) Hepatotoxicity
Ayse L. Mindikoglu
Arie Regev
Pablo A. Bejarano
Enrique J. Martinez
Lennox J. Jeffers
Eugene R. Schiff
Digestive Diseases and Sciences, 2007, 52 : 598 - 601
[6] Stem cell collection in chronic myeloid leukemia patients with cytogenetic response to imatinib mesylate (STI 571, gleevec)
Hardan, I
Lennard, A
Nagler, A
Shimoni, A
Sareli, R
Boque, C
Canzio, M
Olavarria, E
Niederwieser, D
BONE MARROW TRANSPLANTATION, 2003, 31 : S62 - S62
[7] Imatinib mesylate (Gleevec) hepatotoxicity
Mindikoglu, Ayse L.
Regev, Arie
Bejarano, Pablo A.
Martinez, Enrique J.
Jeffers, Lennox J.
Schiff, Eugene R.
DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (02) : 598 - 601
[8] Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
El Jurdi, Najla
Bankoff, Mark
Klein, Andreas
Saif, Muhammad W.
CUREUS, 2016, 8 (06):
[9] In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia
La Rosée, P
Johnson, K
O'Dwyer, ME
Druker, BJ
EXPERIMENTAL HEMATOLOGY, 2002, 30 (07) : 729 - 737
[10] Hypophosphatemia observed in chronic myeloid leukemia patients treated with imatinib mesylate (Gleevec®) is related to digestive side-effects.
Legros, Laurence
Breuil, Veronique
Ferrari, Patricia
Testa, Jean
Cassuto, Jill-Patrice
BLOOD, 2006, 108 (11) : 274B - 274B

← 1 2 3 4 5 →